Bausch Health Companies (TSE:BHC) Stock Price Down 0.9% - Time to Sell?

Key Points

• Shares down 0.9% — Bausch Health traded as low as C$7.61 and last at C$7.62 with ~349,583 shares changing hands (about 24% below average), and the stock sits near its 50‑day SMA (C$7.59) well below its 200‑day SMA (C$8.58).
• Recent results were weak: the company reported a quarterly loss of C($0.41) EPS on C$6.62 billion in revenue, with a negative return on equity (−20.27%) but a small positive net margin (1.82%).
• Valuation and balance‑sheet signals are mixed — market cap C$2.85 billion, P/E 18.14 and PEG 0.21, yet concerning liquidity and leverage metrics include a quick ratio of 0.58, current ratio 1.47 and an extreme reported debt‑to‑equity of −3,835.02.

Bausch Health Companies Inc. (TSE:BHC - Get Free Report)'s share price was down 0.9% on Monday . The company traded as low as C$7.61 and last traded at C$7.62. Approximately 349,583 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 459,399 shares. The stock had previously closed at C$7.69.

Bausch Health Companies Trading Down 0.9%

The stock has a market cap of C$2.85 billion, a PE ratio of 18.14, a P/E/G ratio of 0.21 and a beta of 0.59. The firm has a 50-day simple moving average of C$7.59 and a 200-day simple moving average of C$8.58. The company has a quick ratio of 0.58, a current ratio of 1.47 and a debt-to-equity ratio of -3,835.02.

Bausch Health Companies (TSE:BHC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 18th. The company reported C($0.41) EPS for the quarter. Bausch Health Companies had a negative return on equity of 20.27% and a net margin of 1.82%.The company had revenue of C$6.62 billion during the quarter. Equities analysts forecast that Bausch Health Companies Inc. will post 5.5472637 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.